TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04990076

Intervention type: PROCEDURE
Intervention: Hysterectomy
Description: Surgery includes different types of hysterectomy: vaginal hysterectomy, total abdominal hysterectomy and laparoscopic or Robotic hysterectomy. The type of hysterectomy does not influence histological outcome, as long as the uterus is removed in one part (no power morcellation). Indications for surgery and the type of surgery are according to the departments' protocols. If the patient is deemed to be inoperable due to the extent of the disease, a representive biopsy (e.g. trucut biopsy) will be accepted if sufficiently motivated by the oncology team.
Study: NCT00862602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepping Up to Health
Description: Internet-mediated pedometer-based intervention with gradually increasing goals and feedback on step counts. Also includes educational content targeted at women who have had gestational diabetes about exercise, diet \& nutrition and prevention.
Study: NCT03139201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OxyAqua
Description: OxyAqua (olifilcon D) silicone hydrogel soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Si-Hy
Description: Si-Hy (oliflcon B) silicone hydrogel soft contact lens
Study: NCT02498821

Intervention type: DEVICE
Group type: OTHER
Intervention: Chest X-ray
Description: A Chest X-ray will be taken after healthcare providers have inserted the PICC to make sure it is in the correct location. The X-ray can tell your healthcare providers where the PICC is and whether is has been inserted correctly.
Study: NCT02078037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Sun cooling device
Description: The Arctic Sun® 5000 Temperature management systems (Bard Medical), a non- invasive, surface cooling technology that allows rapid and precise manipulation of core body temperature will be employed to maintain normothermia (normal temperature) in patients with ICH randomized to the treatment group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patient will be given standard fever management (acetaminophen + cooling blanket at the discretion of the treating physician)
Study: NCT03864432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin 25mg
Description: Gemigliptin 50mg 1/2T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin 50mg
Description: Gemigliptin 50mg 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin 100mg
Description: Gemigliptin 50mg 2T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemiglptin 50mg multiple dose
Description: Gemigliptin 50mg 1T \* 10days
Study: NCT00107588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement for homework completion
Description: Provides contingent reinforcement for engaging in homework activities designed to enhance coping skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reinforcement for Abstinence
Description: Provides contingent reinforcement for submitting marijuana-free urine specimen

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management
Description: Will control for the effect of therapist-client contact by providing supportive case management as an active control condition.
Study: NCT03590470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of a nurse-led model of care
Description: A nurse-model of care consisting of a specifically trained geriatric nurse expert, communication and quality improvement tools will be implemented in 11 nursing homes in the German speaking part of Switzerland
Study: NCT00530166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-18054478
Description: 3(100 mg) tablets once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sham comparator
Description: 3(100 mg) tablets once daily for 12 weeks
Study: NCT04153656

Intervention type: OTHER
Group type: OTHER
Intervention: Reading and studying Spiritual Flow
Description: The Wellbeing Inventory will be administered to subjects and they will be compensated upon completion of the survey. Two months after the first survey, the Wellbeing Inventory will be administered to subjects and they will be compensated upon completion of the survey.
Study: NCT04058912

Intervention type: GENETIC
Intervention: PTEN-AKT-FOXO3 Gene Expression
Description: In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.
Study: NCT02498821

Intervention type: DEVICE
Group type: OTHER
Intervention: Sherlock 3CG® TCS
Description: The Sherlock 3CG® TCS is a device that is placed on the subject during the PICC insertion procedure, which helps your healthcare providers know where the PICC is as the healthcare providers are inserting it. It uses magnets and measures electrical activity of the heart to determine the location of the catheter in your body.
Study: NCT00620919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1068 (Synthetic Human Secretin)
Description: Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
Study: NCT04049227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study: NCT02498821

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peripherally Inserted Central Catheter (PICC)
Description: A peripherally inserted central catheter (PICC) is a form of intravenous access that can be used for a prolonged period of time (e.g., for chemotherapy, antibiotics, total parenteral nutrition)
Study: NCT04049227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study: NCT00525304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management program for chronic illness
Description: Self-management program for chronic illness will include between 10 and 16 psychoeducational and supportive group sessions.
Study: NCT01484002

Intervention type: DEVICE
Intervention: Total hip arthroplasty
Description: Replacement of a patient's native hip with an artificial implant featuring a metal-on-polyethylene articulation

Intervention type: DEVICE
Intervention: Total hip arthroplasty
Description: Replacement of a patient's native hip with an artificial implant featuring a metal-on-polyethylene articulation
Study: NCT02106156

Intervention type: DRUG
Intervention: Pegylated interferon alfa-2a
Description: Pegylated interferon alfa-2a administered according to corresponding summary of product characteristics (SmPC).
Study: NCT02494011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional exercise
Description: mobilization stretching exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional exercise
Description: mobilization stretching exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional exercise
Description: mobilization stretching exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Russian current stimulation
Description: stimulation to wrist flexors for 15 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: closed kinetic chain exercise
Description: wall press exercise plyometric exercise
Study: NCT03901300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fundamental Motor Skills App
Description: Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized experimental group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unstructured Physical Activity App
Description: Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized active comparator group.
Study: NCT03593629

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 6-month PrEP + blood-based HIV self-test
Description: Participants receive 6-month PrEP supply plus two blood-based HIV self-tests (Atomo Diagnostics Blood-Based HIV-1 Self-Testing Kit) for quarterly HIV testing.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 6-month PrEP + oral fluid HIV self-test
Description: Participants receive 6-month PrEP supply plus two oral fluid HIV self-tests (OraQuick Oral Fluid-based HIV-1 Self-Testing Kit) for quarterly HIV testing.
Study: NCT04490915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crinecerfont
Description: CRF1-receptor antagonist
Study: NCT02106156

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin administered according to corresponding summary of product characteristics (SmPC).
Study: NCT00455637

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Study: NCT01068561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravitreal injection of autologous bone marrow stem cells
Description: One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
Study: NCT03384056

Intervention type: DEVICE
Intervention: Self Pressurized Airway Device with Blocker
Description: used in adult low risk females undergoing elective gynecological operations

Intervention type: DEVICE
Intervention: Proseal Laryngeal Mask Airway
Description: used in adult low risk females undergoing elective gynecological operations.
Study: NCT03059290

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neolix file
Description: first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani ,Japan ) is loose or pass easily in the canal , but in case of K-file size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length to the full working length with (X-Smart, Dentsply Maillefer, USA.), with speed 300-500 rpm and torque 1.5 N.cm
Study: NCT02765841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomitapide
Study: NCT03319199

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SLIM WATER
Description: 2 grams of L- CARNITINE and 150 mg MAGNESIUM for a duration of 16 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - water
Description: for a duration of 16 weeks
Study: NCT02882607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mzanga Samala Moyo Wako ([Mzanga] Peer Groups
Description: 8 small group sessions led by community young women, focused on reproductive health, including HIV, STI and unintended pregnancy prevention; includes skill-building for self-efficacy
Study: NCT04482465

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sample
Description: blood sample to determine omega6/omega 3 ratio, EPA, DHA, zinc, cupric oxide, vitamine D
Study: NCT04313855

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SMS in the early detection of postoperative neuropathic pain
Description: 7 days after the intervention, the patient receives a standardized questionnaire by SMS, to determine whether the patient has pain at the operating site and whether this pain has the characteristics of neuropathic pain. After replying to the SMS, the patient will be contacted by phone to assess: the intensity of pain at the operating site using a numerical scale and the existence of neuropathic pain. Depending on the responses received by SMS and/or phone, a consultation appointment with an anesthesiologist specializing in pain may be offered within a maximum of 2 weeks.~Ninety days after your surgery, the patient receives the same standardized questionnaire by SMS. The patient will be contacted by telephone, in order to assess the intensity of pain at the operating site and the existence of neuropathic pain using. If the patient has post-operative pain, a consultation appointment with an anesthesiologist specializing in pain will be offered to him within a maximum of 2 weeks.
Study: NCT03247933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine: Maintenance Respiratory Rehabilitation
Description: Telemedicine: Maintenance Respiratory Rehabilitation. Patients will receive a personal program of maintenance respiratory rehabilitation supported by telemedicine (TeleRR).~A personal program of Respiratory rehabilitation consists on: 20-30 minutes of static bicycle exercises + 3 series of ten repetitions from 4 different types of exercises with weights / cufflinks. 3 days a week, every week for a year.~They will be in their homes doing the program of treatment prescribed by the physician. They will be provided with the material that is needed: 1 static bicycle, 2-weights / cufflinks, 3-device mobile (smartphone/PDA) + Pulse Oximeter.~The patient must send the exercises every day that are scheduled training exercises once have been completed.
Study: NCT01923753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerosure at 15 Hz
Description: Active Aerosure HFAO device operating at lower frequency

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerosure at 25 Hz
Description: Active Aerosure HFAO device operating at higher frequency

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Aerosure
Description: Deactivated but identical Aerosure HFAO device
Study: NCT01381653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: HIV prevention intervention
Description: Substance using HIV-negative young men who have sex with men who engage in sexual risk and use social networking (Facebook) will be recruited and enrolled in a brief intervention utilizing Motivational Interviewing over chat window to reduce their substance use and sexual risk. They will also evaluate their intervention experience at the end of their eight sessions and post-assessment.
Study: NCT02973685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemoembolization
Description: Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox Protocol
Description: oxaliplatin,leucovorin and 5-FU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE Drug Protocol
Description: lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, with or without MMC) followed by polyvinyl alcohol particles (PVA)
Study: NCT03427944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Dobesilate group
Description: Calcium dobesilate was used to treat patients with chronic renal failure on the basis of conventional treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Treatment group
Description: Conventional treatment were used to treat patients with chronic renal failure.
Study: NCT02304211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin will be administered either into the radial artery (microdose intervention) or IV (systemic intervention).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin will be administered either into the radial artery (microdose intervention) or IV (systemic intervention).
Study: NCT03886935

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomics

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomics
Study: NCT04140877

Intervention type: DEVICE
Group type: OTHER
Intervention: Visu
Description: An experimental (test) virtual reality display

Intervention type: DEVICE
Group type: OTHER
Intervention: Visu
Description: An experimental (test) virtual reality display
Study: NCT01419093

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: 5 A communication intervention
Description: This study will examine the effect of primary care clinicians' communication intervention linked to a community-based exercise program. We will use the 5As in discussion of physical activity in 371 office visits in an ethnically diverse, primarily low income patient population. Secondary and exploratory aims are to provide pilot information on \[feasibility and sustainability of the intervention from the patients' and clinicians' perspective and derive effect sizes on the intervention's effect on objective changes in physical activity in a subset of participants.
Study: NCT00462228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
Study: NCT01958450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: acne scar treatment using Er:YAG laser

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar radiofrequency with diode laser
Description: acne scar treatment with bipolar radiofrequency combined with diode laser
Study: NCT04461379

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: A single dose BCG vaccine intradermally (deltoid region of the right arm) 0.1 ml, equivalent to 0.075 mg of attenuated Mycobacterium bovis . (Tokio 172 strain)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose intradermally ((deltoid region of the right arm) 0.1 ml of NaCl 0.9% solution
Study: NCT04490915

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crinecerfont
Description: CRF1-receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active dosage form
Study: NCT02110693

Intervention type: OTHER
Group type: OTHER
Intervention: Interviewer and tablet administration of the TAPS Tool
Description: All participant will self-administer substance use screening instrument (TAPS Tool) on a tablet computer and will be administered the TAPS Tool by an interviewer.
Study: NCT04444050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986331
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986331
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986331
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986331
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986331
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986331
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986331
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986331
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986331
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986331
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986331
Description: Specified dose on specified days
Study: NCT00361530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Study: NCT03304457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine 10mg once daily orally for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 80mg once daily orally for 6 weeks
Study: NCT03192579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPA and high dose rosuvastatin
Description: After randomization, patients with intensive lipid lowering therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard dose rosuvastatin
Description: After randomization, patients with standard lipid lowering therapy start only rosuvastatin (2.5mg/day) for 12 months.
Study: NCT02101008

Intervention type: DRUG
Group type: OTHER
Intervention: disulfiram and chelated zinc